Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2010

Open Access 01-05-2010 | Gastrointestinal Oncology

Is Lymphadenectomy a Predictor or Savior for Patients with Gastric Cancer?

Authors: Hiroya Takeuchi, MD, PhD, Yuko Kitagawa, MD, PhD, FACS

Published in: Annals of Surgical Oncology | Issue 5/2010

Login to get access

Excerpt

In the history of surgical oncology, survival benefit of extended lymphadenectomy has been a focus of debates in gastrointestinal carcinomas.1 The fear for the invisible metastasis prompted surgeons to perform more aggressive resections with lymphadenectomy to control the disease locally. However, the clinical significance of extended lymphadenectomy has been the subject of controversy over the past 10 years.2‐4 On the other hand, the histopathological status of regional lymph nodes is one of the most reliable predictors of recurrence and overall survival for most gastrointestinal cancer, and it is often used to justify stratification of patients for adjuvant therapy. …
Literature
1.
Takeuchi H, Kitajima M, Kitagawa Y. Sentinel lymph node as a target of molecular diagnosis of lymphatic micrometastasis and local immunoresponse to malignant cells. Cancer Sci. 2008;99:441–50.CrossRefPubMed
2.
Binenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908–14.CrossRef
3.
Cuschieri A, Weeden S, Fielding J, et al. Patients survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79:1522–30.CrossRefPubMed
4.
Wu CH, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomized controlled trial. Lancet Oncol. 2006;7:309–15.CrossRefPubMed
5.
Deng J, Liang H, Sun D, et al. The 7th UICC N stage is suitable for prediction the overall survival of gastric cancer patients after curative resection in China. Ann Surg Oncol. 2010; (in press).
6.
Inoue K, Nakane Y, Iiyama H, et al. The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol. 2002;9:27–34.CrossRefPubMed
7.
Bando E, Yonemura Y, Taniguchi K, et al. Outcome of ratio of lymph node metastasis in gastric carcinoma. Ann Surg Oncol. 2002;9:775–84.CrossRefPubMed
8.
Maduekwe U, Lauwers G, Fernandez-del-Castillo C, et al. A new metastatic lymph node ratio system reduces stage migration inpatients undergoing D1 lymphadenectomy for gastric adenocarcinoma: analysis of 257 consecutive cases at a single Western institution. Ann Surg Oncol. 2010; (in press).
9.
Sun Z, Zhu GL, Lu C, et al. The impact of N-ration in minimizing stage migration phenomenon in gastric cancer patients with insufficient number or level of lymph node retrieved: results from a Chinese mono-institutional study in 2159 patients. Ann Oncol. 2009;20:897–905.CrossRefPubMed
10.
Sasako M, Saka M, Fukagawa T, et al. Modern surgery for gastric cancer. Japanese perspective. Scand J Surg. 2006;95:232–5.PubMed
Metadata
Title
Is Lymphadenectomy a Predictor or Savior for Patients with Gastric Cancer?
Authors
Hiroya Takeuchi, MD, PhD
Yuko Kitagawa, MD, PhD, FACS
Publication date
01-05-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 5/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-0942-2

Other articles of this Issue 5/2010

Annals of Surgical Oncology 5/2010 Go to the issue

Colorectal Cancer

Management of Recurrent Rectal Cancer

Breast Oncology

p53 as a Marker of Prognosis in African-American Women with Breast Cancer

Pancreatic Tumors

Distal Pancreatectomy Combined with Celiac Axis Resection in Treatment of Carcinoma of the Body/Tail of the Pancreas: A Single-Center Experience

Translational Research and Biomarkers

EMAP II-Based Antiangiogenic-Antiendothelial In Vivo Combination Therapy of Pancreatic Cancer

Gastrointestinal Oncology

Tumorigenic Role of Podoplanin in Esophageal Squamous-Cell Carcinoma

Translational Research and Biomarkers

HLA-G Expression in Human Breast Cancer: Implications for Diagnosis and Prognosis, and Effect on Allocytotoxic Lymphocyte Response After Hormone Treatment In Vitro